BioPharm Insight™, a division of Pearson PLC (NYSE: PSO), and i3 Pharma Informatics today announced an alliance that will bring healthcare claims information to clinical operations professionals, assisting in patient enrollment, physician and site selection, and feasibility analysis.
“i3 Pharma Informatics is the provider of investigator and site information based on patient counts from a large database of information relating to private claims. They are often the last, best hope for rescuing a trial from enrollment failures. This one of a kind alliance allows us to include information on investigators and sites from claims data in our clinical operations database, BioPharm Clinical, significantly enriching our physician profiles. In my experience in the information business, this represents the holy grail – the data is proprietary, highly relevant to the needs of the end user, and helps solve a mission critical need which is optimizing the patient recruitment process,” said Sean Power, President and Founder of BioPharm Insight.
16 Nov 2009:
BioPharm Clinical will now allow clinical operations professionals to:
Thomas Abbott, president of i3 Pharma Informatics, said, “BioPharm Insight has long been recognised as a premier information provider to our shared biotech and pharmaceutical client base. They are the most innovative miner of information out of disparate data sources, and the insight they can develop using their technologies is quite remarkable. I am sure that the combination of our unique skill sets will be a win-win, not only for us, but for the industry as a whole.”
Bill Gwinn, vice-president of Clinical Informatics at i3, commented, “By providing the investigator and site information from claims data from a large medical insurance company in the US, i3 has made BioPharm Insight a rich starting point for planning a clinical trial. When needed, i3 can go further in customised analysis, showing the count of patients by doctor who exactly match all the criteria in a trial protocol. Our studies prove that the top-ranking investigators enroll patients twice as fast.”